ReviewCancers2025

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers.

Nusayba A Bagegni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.